SUMMARY

PRISM is an innovative venture investment vehicle that targets emerging companies at the intersection of healthcare and artificial intelligence (AI). Leveraging deep industry insights and extensive research, PRISM aims to build a diversified portfolio of pioneering companies that innovate within drug discovery, clinical trials, personalized medicine, and healthcare operational efficiencies.

Indications of Interest and Allocation Reservation Form

MARKET CONTEXT

The potential for AI in life sciences is more pronounced now due to advancements in AI technology and data analytics, increased computational power, and the accumulation of vast biological datasets. Previously, limitations in computational capabilities and the lack of comprehensive data made it challenging to apply AI effectively. Now, with more sophisticated AI models and improved data availability, there's a unique opportunity to accelerate drug discovery, tailor treatments to individual patients, and streamline healthcare processes, making investment in this area particularly promising.

The market backdrop for PRISM is set against a transformative global economic landscape, significantly influenced by advancements in artificial intelligence (AI), precision medicine, and digital health.

·      AI's expected impact on the global economy is anticipated to exceed $15 trillion by 2030, showcasing AI's immense potential across various sectors, including life sciences and healthcare.

·      Concurrently, the global precision medicine market is on track to surpass $157 billion by 2027, reflecting the growing demand for tailored healthcare solutions that leverage genetic, environmental, and lifestyle factors to optimize patient care.

·      Moreover, the digital health market is projected to exceed $4.5 trillion by 2029, underlining the accelerated adoption of digital technologies in transforming healthcare delivery, patient monitoring, and disease management. *

INVESTMENT THESIS

PRISM's investment thesis is predicated on the conviction that the intersection of life sciences and artificial intelligence (AI) represents an unparalleled opportunity for transformative growth and innovation. We believe that this nexus is not just the future of healthcare but also a pivotal area for generating substantial returns for our investors. Our thesis is built on several core pillars:

1. Untapped Potential in AI and Healthcare: The integration of AI in healthcare is still in its nascent stages, despite its proven capability to revolutionize diagnostics, treatment personalization, drug discovery, and patient care. PRISM aims to harness this potential by investing in companies that are pushing the boundaries of what AI can achieve in life sciences.

2. Driving Efficiency and Effectiveness: AI technologies offer unprecedented opportunities to enhance the efficiency of healthcare delivery and the efficacy of treatments. By focusing on companies that leverage AI to streamline operations, reduce costs, and improve outcomes, PRISM seeks to contribute to a more sustainable and effective healthcare ecosystem.

3. Personalized Medicine and Patient Outcomes: The shift towards personalized medicine, powered by AI, holds the promise of significantly improved patient outcomes. PRISM invests in companies that use AI to analyze vast datasets, including genetic information, to tailor treatments to individual patients, thus moving away from the one-size-fits-all approach.

4. Innovation in Drug Discovery and Development: The drug discovery and development process is notoriously time-consuming and costly. AI can drastically reduce both the time and expense involved by predicting drug efficacy and optimizing clinical trials. PRISM targets investments in companies employing AI to make these processes more efficient and to bring life-saving treatments to market faster.

5. Scalability Through Digital Health Solutions: Digital health solutions, including telemedicine, wearable technologies, and health monitoring apps, are scaling the reach of healthcare services. PRISM is interested in companies that are innovating in digital health, using AI to enhance accessibility, continuity of care, and patient engagement.

6. Ethical and Sustainable Impact: PRISM is committed to investing in companies that not only have strong financial prospects but also adhere to ethical AI practices and contribute positively to societal health outcomes. We believe that responsible investments in AI can drive a significant positive impact on global health challenges.

7. Strategic Partnerships and Collaborations: Recognizing the complexity of healthcare challenges, PRISM values companies that engage in strategic partnerships and collaborations across industries and sectors. Such collaborations can accelerate innovation, foster cross-disciplinary approaches, and enhance market access.

In essence, PRISM's investment thesis is centered on the belief that AI has the power to redefine healthcare as we know it, making it more personalized, efficient, and accessible. By strategically investing in cutting-edge companies at the forefront of this revolution, PRISM aims to deliver not only financial returns but also to contribute to the advancement of global healthcare.

PARTICIPATION

Participation in PRISM is by invitation only. Allocations will be given to existing investors first, then on a first come, first serve basis.

To make a reservation, please register here.

SUMMARY RISK FACTORS

Investing in life sciences, technology, and artificial intelligence (AI) sectors carries unique risks that should be carefully considered by investors. The following are key risk factors associated with investments in these areas. Please refer to the Fund’s offering documents for a full set of risk factors. Regulatory and Compliance Risks: Life sciences companies often face significant regulatory hurdles, including obtaining approvals from bodies like the FDA. Changes in regulations or failure to comply can impact company performance and investment returns. Technological Obsolescence: Rapid advancements in technology and AI can render existing products or solutions obsolete. Companies failing to innovate or adapt may quickly lose market relevance and value. Intellectual Property Risks: The value of life sciences and tech companies often hinges on intellectual property (IP) rights. Litigation over IP issues or infringement can result in substantial costs and impact the valuation of these companies. Market Acceptance and Competition: Success in these sectors is highly dependent on market acceptance. Even innovative products may fail to achieve commercial success. Additionally, high levels of competition can impact market share and profitability. Funding and Liquidity Risks: Many life sciences and tech ventures require substantial capital for R&D and operations. There is a risk of insufficient funding, which can impact a company's ability to continue operations or achieve its goals. Clinical and Developmental Risks: In life sciences, products typically undergo rigorous clinical trials. There is a risk that these products may not achieve desired results, leading to loss of investment and time. AI Ethics and Social Acceptance: AI investments are subject to ethical considerations and public perception. Negative societal response or ethical concerns can influence the success of AI-related ventures. Dependence on Key Personnel: The success of ventures in these sectors often depends heavily on the talent and expertise of a limited number of individuals. Loss of key personnel can adversely affect a company’s performance. Data Security and Privacy Risks: Companies in technology and AI are often responsible for handling large volumes of sensitive data, making them targets for cyberattacks and putting them at risk of data breaches. Economic and Political Factors: Global economic conditions, political instability, and changes in government policies can significantly impact these sectors, particularly in areas such as funding, regulation, and international trade. Product Liability and Safety: Companies in the life sciences sector are exposed to risks related to product safety and liability. Any harm caused by their products can lead to legal action and damage to reputation. Supply Chain Risks: Tech and life sciences companies often rely on complex global supply chains. Disruptions in these supply chains can significantly impact operations and costs.

This website is a general communication being provided for informational purposes only. It is educational and not designed to be taken as advice or a recommendation for any specific investment product, strategy, plan feature, or other purposes in any jurisdiction, nor is it a commitment to participate in any of the transactions mentioned herein. Any examples used are generic, hypothetical, and for illustration purposes only. This material does not contain sufficient information to support an investment decision, and it should not be relied upon by you in evaluating the merits of investing in any securities or products. Investors should ensure that they obtain all relevant information before investing. Any forecasts, figures, opinions, or investment techniques and strategies are subject to change and may not come to pass. All information presented herein is considered to be accurate at the time of production, but no warranty of accuracy is given, and no liability in respect of any error or omission is accepted. Investments involve risks, the value of investments and the income from them may fluctuate under market conditions and taxation agreements, and investors may not get back the full amount invested. Past performance and yields are not reliable indicators of current and future results. Consult with your CPA, attorney, or financial advisor before investing. Financial and operating risks are significant when investing in private companies. Loss of an Investor’s entire investment is possible and can easily occur. Past performance is not a guarantee of future returns. Before entering into any transaction, investors should determine any economic risks and benefits, as well as any legal, tax and accounting consequences of doing so, as well as their ability to assume such risks. Forecasts, calculations, or estimates presented are subject to change and may not come to pass.
This website is not an offering.